Natera Acquires Foresight, Enhancing Solid Tumor MRD Detection Capabilities
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 50 minutes ago0mins
- Technology Integration: Natera's acquisition of Foresight for $275 million enhances its solid tumor MRD detection capabilities through the integration of Foresight's ultrasensitive phased variant technology, which is expected to accelerate adoption in lymphoma and other solid tumors.
- Market Expansion: This acquisition combines Natera's MRD testing capabilities with Foresight's strong clinical position in lymphoma, potentially driving demand for testing in over 75,000 new lymphoma cases annually in the U.S.
- Intellectual Property Enhancement: The acquisition expands Natera's patent portfolio to over 500 issued or pending patents, further solidifying its market leadership in personalized MRD testing and enhancing its competitive edge in precision oncology.
- Clinical Application Outlook: The integrated PhasED-Seq technology is expected to be launched for clinical use in 2026, providing biopharma and academic partners with more efficient MRD testing, thereby advancing clinical trials and translational research efforts.
NTRA.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 238.210
Low
172.00
Averages
233.50
High
280.00
Current: 238.210
Low
172.00
Averages
233.50
High
280.00
JPMorgan
NULL -> Overweight
maintain
$240 -> $250
2025-11-25
Reason
JPMorgan
Price Target
$240 -> $250
2025-11-25
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Natera to $250 from $240 and keeps an Overweight rating on the shares. The firm updated the company's model.
UBS
Buy
upgrade
$218 -> $280
2025-11-18
Reason
UBS
Price Target
$218 -> $280
2025-11-18
upgrade
Buy
Reason
UBS raised the firm's price target on Natera to $280 from $218 and keeps a Buy rating on the shares.
Stephens
Stephens
Overweight
maintain
$17 -> $235
2025-11-13
Reason
Stephens
Stephens
Price Target
$17 -> $235
2025-11-13
maintain
Overweight
Reason
Stephens raised the firm's price target on Natera to $235 from $17 and keeps an Overweight rating on the shares after the company reported "another strong beat." The firm continues to view Natera as "one of the most attractive organic growth stories" within diagnostics, the analyst tells investors.
Stephens
Stephens
Overweight
maintain
$197 -> $235
2025-11-13
Reason
Stephens
Stephens
Price Target
$197 -> $235
2025-11-13
maintain
Overweight
Reason
Stephens raised the firm's price target on Natera to $235 from $197 and keeps an Overweight rating on the shares after the company reported "another strong beat." The firm continues to view Natera as "one of the most attractive organic growth stories" within diagnostics, the analyst tells investors.
See All Ratings
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why did Natera's stock price increase by 12.90% last week?
What factors contributed to Exact Sciences Corporation's 48.97% stock surge?
Will Natera's stock continue to rise following UBS's price forecast increase?
Could Alphabet's regulatory challenges impact its stock performance in the coming weeks?